Mergers & Acquisitions
Filter News
Found 20,936 articles
-
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
5/8/2023
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.
-
Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions
5/8/2023
Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.
-
Zomedica Exercises Option to Acquire Structured Monitoring Products
5/8/2023
Zomedica Corp., announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc., the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price.
-
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
5/8/2023
Neuro3 Therapeutics announced the signing of an exclusive, worldwide license and option agreement with Lundbeck, a leading pharmaceutical company focusing on the development of innovative medicines treating neurological and psychiatric diseases.
-
TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings
5/5/2023
TTG Imaging Solutions, LLC announced the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. The acquisition closed on May 4, 2023.
-
Headlands Research Acquires Clinvest Research — the Clinical Research Site Network’s Third Addition of 2023
5/4/2023
Headlands Research, a leading multinational network of clinical trial sites, announced the acquisition of Clinvest Research, an established site based in Springfield, Missouri.
-
Hasten Biopharma Acquires Commercial Rights in China for Roche's Antibiotic Rocephin®
5/4/2023
Hasten Biopharmaceutic Co., Ltd announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.
-
Centene Corporation Signs Definitive Agreement to Divest Apixio to New Mountain Capital
5/3/2023
Centene Corporation announced that it has signed a definitive agreement to sell Apixio, a leading artificial intelligence platform that enables value-based care, to New Mountain Capital, a growth-oriented investment firm with more than $37 billion in assets under management.
-
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
5/3/2023
Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Universal Display Corporation Acquires Merck KGaA, Darmstadt, Germany’s Phosphorescent OLED Emitter Intellectual Property Assets and Enters into Multi-Year Collaboration Agreement
5/3/2023
Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today that through its wholly-owned subsidiary UDC Ireland Limited, UDC has acquired the Phosphorescent OLED Emitter Intellectual Property (IP) assets of Merck KGaA, Darmstadt, Germany, a leading science and technology company.
-
Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation
5/3/2023
Avertix Medical, Inc. and BIOS Acquisition Corporation announced that the companies have entered into a definitive merger agreement for a business combination that would result in Avertix becoming a publicly traded company on Nasdaq.
-
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
5/2/2023
Eterna Therapeutics Inc. today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics (“Exacis”).
-
Stryker completes acquisition of Cerus Endovascular
5/2/2023
Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms.
-
Calibre Scientific Completes the Acquisition of Eppendorf’s Micro Manipulation Product Portfolio and Assumes Control of Sales and Service Operations
5/2/2023
Calibre Scientific, a leading global life science company, is pleased to announce the successful completion of the acquisition of the micro manipulation product portfolio from Eppendorf SE.
-
3M enters agreements with Pierrel for the sale of assets associated with the dental local anesthetic business
5/2/2023
3M announced it has entered into agreements to sell certain assets associated with its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A., a global provider of services for the pharmaceutical industry, for a purchase price of $70 million, subject to closing and other adjustments.
-
Japanese biopharma scoops up Iveric’s investigational drug for age-related blindness disease. The drug, which trails Apellis’ Syfovre, is awaiting FDA approval with a decision expected by August.
-
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
5/1/2023
Astellas Pharma Inc. and Iveric bio, Inc. announced that on April 29, 2023, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.
-
NuVasive Shareholders Approve Merger Agreement with Globus Medical
4/27/2023
NuVasive, Inc. (NASDAQ: NUVA) today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company's merger agreement with Globus Medical (NYSE: GMED).
-
Abbott Completes Acquisition of Cardiovascular Systems, Inc.
4/27/2023
Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
-
Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments
4/27/2023
Starton Therapeutics, Inc. and Healthwell Acquisition Corp. today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which, among other things, HWEL Holdings Corp., a newly formed wholly-owned subsidiary of Healthwell (“Pubco”), has agreed to acquire Starton and become a publicly traded company (the “Transaction”).